- Abdominal aortic calcification in patients with inflammatory bowel disease: does anti-tumor necrosis factor α use protect from chronic inflammation-induced atherosclerosis?
-
Mantaka A, Galanakis N, Tsetis D, Koutroubakis IE
- KMID: 2535823
- Intest Res.
- 2022 Oct;20(4):495-505.
- doi: 10.5217/ir.2022.00017
Background/Aims: Abdominal aortic calcium (AAC) deposition has been suggested as a marker of early atherosclerosis. There is no published data on the evaluation of AAC in inflammatory bowel disease (IBD). Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
-
Theodoraki E, Orfanoudaki E, Foteinogiannopoulou K, Legaki E, Gazouli M, Koutroubakis IE
- KMID: 2521609
- Intest Res.
- 2021 Oct;19(4):461-467.
- doi: 10.5217/ir.2020.00042
Background/Aims: The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs)... -
- CITED
-
- Close
- SHARE
-
- Close
